Clinical trials and research studies

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

This trial looks at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors (NSCLC, HNSCC).

The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .

The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.

Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

The purpose of the clinical study is to compare the effectiveness of IBP-9414 treatment against placebo in preventing necrotizing enterocolitis in premature infants.

Treatments: Prevention of necrotizing enterocolitis in premature infants

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).